Meropenem Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Injection
Available Strengths: 500 mg/vial, 1 g/vial
Reference Brands: Merrem IV(US)
Category:
Critical Care
Meropenem is a potent IV carbapenem antibiotic used for serious infections like pneumonia and sepsis. Available in 500 mg and 1 g vials and infusions, brands include Merrem, Meronem, and generics. Meropenem is a high-demand product on pharma B2B platforms for hospital and critical care procurement.
Meropenem is available in Intravenous (IV) Injection
and strengths such as 500 mg/vial, 1 g/vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Meropenem is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Meropenem can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Meropenem is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections, including pneumonia, intra-abdominal infections, meningitis, and sepsis. It is administered intravenously and is available as a lyophilized powder in 500 mg and 1 g vials, as well as ready-to-use infusions. In the US, Meropenem is marketed as Merrem IV (Pfizer) and distributed by Sagent, Fresenius, and Hikma. In the EU, it is available under the brand Meronem and from Accord, Kabi, and Mylan. Hospitals and ICUs frequently procure Meropenem through pharma B2B platforms for its efficacy against multidrug-resistant gram-negative and gram-positive bacteria.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing